ArticleGynecologic oncology reports2023

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.

Blair McNamara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.